Oral small-molecule PTH1R agonists as alternative therapy option for PTH-related disorders
June 7, 2024
Researchers from Septerna Inc. presented the discovery and preclinical characterization of novel parathyroid hormone PTH1 receptor (PTH1R) agonists being developed as a new treatment option against hypoparathyroidism.